Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates of ...

In a report released on January 21, Akash Tewari from Jefferies reiterated a Buy rating on Pfizer (PFE – Research Report). The company’s shares ...

However, Pfizer's revenue guidance for 2025 doesn't look particularly exciting. The company expects its top line to come in ...

The pharma expects a modest financial headwind this year from changes to Medicare prescription drug benefits under the Inflation Reduction Act.

President Trump has vowed to impose tariffs on China, Mexico, and Canada. They could make common medicines less affordable.

Maybe your mom reassured you when you were younger that the cough syrup would taste "just like candy" -- usually cherry, but ...

We recently compiled a list of the 15 Best Cheap Stocks to Buy for 2025. In this article, we are going to take a look at ...

Obesity continues to grab attention at the J.P. Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera ...

Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Pfizer (PFE – Research Report) and keeping the price target at $36.00.Stay ...

A U.S. appeals court on Friday revived a lawsuit by a conservative group opposed to diversity initiatives in medicine that ...

A post-marketing review by the FDA detected an increased risk of the autoimmune condition in patients inoculated with GSK’s Arexvy and Pfizer’s Abrysvo, prompting the regulator to require adjustments ...

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...